- Home
- DLXY vs IMNN Comparison
DLXY vs IMNN Comparison
Compare DLXY & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLXY | IMNN |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 12.5M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | DLXY | IMNN |
|---|---|---|
| Price | $0.98 | $3.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 42.1K | 32.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.37 |
| 52 Week High | $7.00 | $9.32 |
Technical Indicators
Market Signals| Indicator | DLXY | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 42.15 |
| Support Level | $0.85 | $3.01 |
| Resistance Level | $0.96 | $4.26 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 38.12 | 27.97 |
Price Performance
Historical ComparisonAbout DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).